Celyad SA (CYAD) - Total Liabilities
Based on the latest financial reports, Celyad SA (CYAD) has total liabilities worth €8.80 Million EUR (≈ $10.29 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Celyad SA annual equity growth to track the company's year-over-year net asset growth rate.
Celyad SA - Total Liabilities Trend (2010–2024)
This chart illustrates how Celyad SA's total liabilities have evolved over time, based on quarterly financial data.
Celyad SA Competitors by Total Liabilities
The table below lists competitors of Celyad SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Solartron Public Company Limited
BK:SOLAR
|
Thailand | ฿913.70 Million |
|
Soc Franc Casinos
PA:SFCA
|
France | €9.21 Million |
|
Jwwinvest
WAR:JWW
|
Poland | zł51.00 Million |
|
Raketech Group Holding
ST:RAKE
|
Sweden | Skr29.93 Million |
|
Kamdar Group (Malaysia) Bhd
KLSE:8672
|
Malaysia | RM49.23 Million |
|
Digitree Group S.A
WAR:DTR
|
Poland | zł24.92 Million |
|
BAIYU Holdings Inc.
NASDAQ:BYU
|
USA | $80.25 Million |
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
USA | $6.92 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Celyad SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Celyad SA.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Celyad SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Celyad SA (2010–2024)
The table below shows the annual total liabilities of Celyad SA from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €26.05 Million ≈ $30.45 Million |
+161.05% |
| 2023-12-31 | €9.98 Million ≈ $11.67 Million |
-35.20% |
| 2022-12-31 | €15.40 Million ≈ $18.00 Million |
-57.58% |
| 2021-12-31 | €36.30 Million ≈ $42.44 Million |
+3.46% |
| 2020-12-31 | €35.09 Million ≈ $41.02 Million |
-20.64% |
| 2019-12-31 | €44.22 Million ≈ $51.69 Million |
+14.23% |
| 2018-12-31 | €38.71 Million ≈ $45.26 Million |
+28.64% |
| 2017-12-31 | €30.09 Million ≈ $35.18 Million |
-37.21% |
| 2016-12-31 | €47.92 Million ≈ $56.02 Million |
-0.27% |
| 2015-12-31 | €48.05 Million ≈ $56.18 Million |
+177.89% |
| 2014-12-31 | €17.29 Million ≈ $20.22 Million |
+11.65% |
| 2013-12-31 | €15.49 Million ≈ $18.11 Million |
+2.85% |
| 2012-12-31 | €15.06 Million ≈ $17.60 Million |
+149.42% |
| 2011-12-31 | €6.04 Million ≈ $7.06 Million |
-31.43% |
| 2010-12-31 | €8.80 Million ≈ $10.29 Million |
-- |
About Celyad SA
Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more